A group of advisers to the Centers for Disease Control and Prevention is preparing to vote on whether the agency should scrap its long-standing recommendation that every baby get a hepatitis B vaccina

The nation's top vaccine advisory panel is expected to debate on Thursday whether to delay the first dose of the hepatitis B shot.

As hepatitis B research progresses, achieving higher functional cure rates is becoming more feasible. It is vital that policymakers set clear elimination targets for hepatitis B, coordinate efforts, enhance surveillance, and create supportive regulatory environments to support this.

Of the 723 people with Fibrosis-4 Index scores greater than 3.25, indicating advanced fibrosis, and 587 people with diagnosed cirrhosis or liver decompensation, 43.3% and 40%, respectively, were untreated, they wrote in JAMA Network Open.

Despite untreated HBV being linked to earlier mortality, higher all-cause and liver-related death, and a 10% to 25% lifetime risk of developing hepatocellular carcinoma (HCC), only 29% of qualifying patients in the US receive treatment. 2

GlobalData expects the chronic hepatitis B therapeutics market across major markets to climb from $1.5 billion in 2024 to $3.2 billion in 2034. The projection reflects rising investment in functional cure candidates,

RNAi is a revolutionary and powerful biotech modality that is being utilized for Chronic Hepatitis B. Investors should heed caution as RNAi has been plagued by clinical failures and setbacks. RNAi has not been shown to provide any tangible therapeutic ...

Spontaneous loss of hepatitis B e antigen (HBeAg) followed by seroconversion to anti-HBe usually coincides with normalization of serum alanine aminotransferase (ALT) levels, reduction in HBV DNA in serum (< 1 x 10 6 copies/mL), and a marked reduction in ...